• Home
  • COVID-19
    • Infection Control Program
    • Environment Control Program
  • About Us
    • Leadership
      • Board of Directors
      • Consultants
      • Our Team
    • Partners
  • Product
    • Infectious Diseases – dxn1
      • Rapid Infection Detection (RID)
      • dxn1 BactFast
      • dxn1 FungiFast
      • dxn1 Virfast
    • Predictive – GSeek
      • GSeek Exome
      • GSeek Breast
      • GSeek ColoRectal
      • GSeek Newborn Screening
      • GSeek Carrier Screening
    • Personalized Medicine – GSeek
      • GSeek Tumor Hotspots
    • Fertility – GScan
      • Non-Invasive GScan (NIPT)
  • Services
    • Clinical Diagnosis
    • Research
  • Technology
    • NGS
    • Genetic Consultation
    • Case Studies
      • Local
      • International
      • Archives
  • FAQs
  • Testimonials
  • Contact Us

Credence Genomics Credence Genomics

Credence Genomics

  • Home
  • COVID-19
    • Infection Control Program
    • Environment Control Program
  • About Us
    • Leadership
      • Board of Directors
      • Consultants
      • Our Team
    • Partners
  • Product
    • Infectious Diseases – dxn1
      • Rapid Infection Detection (RID)
      • dxn1 BactFast
      • dxn1 FungiFast
      • dxn1 Virfast
    • Predictive – GSeek
      • GSeek Exome
      • GSeek Breast
      • GSeek ColoRectal
      • GSeek Newborn Screening
      • GSeek Carrier Screening
    • Personalized Medicine – GSeek
      • GSeek Tumor Hotspots
    • Fertility – GScan
      • Non-Invasive GScan (NIPT)
  • Services
    • Clinical Diagnosis
    • Research
  • Technology
    • NGS
    • Genetic Consultation
    • Case Studies
      • Local
      • International
      • Archives
  • FAQs
  • Testimonials
  • Contact Us

Introducing GSeek Breast

Breast cancer is the commonest form of cancer in women.  One in eight women worldwide get affected with breast cancer during their lifetime.  At present, in Sri Lanka, it accounts for 38.7% of all cancers among women who are diagnosed with cancer between 39-46 years of age, ranking first in the age group.  In women who are diagnosed with cancer 15-34 years of age, it is ranked second, contributing for 12.9% out of all cases.

Benefit of GSeek Breast testing

  • Enables healthcare providers to develop personalized medical management plans to significantly reduce the risk of cancer in the patients who are genetically predisposed.
  • Helps in very early diagnosis of disease, increasing treatment outcome and reducing medical costs.
  • Counsel patients and family members on the inheritance pattern of the cancer within the family, suggesting screening for other family members.

What we do

  • We provide timely and accurate clinically actionable diagnostic services that save lives.
  • From the identification of infections and contamination affecting humans and food to inherited disorders and predictive tests for germ-line cancers to personalized treatment for carcinomas.
  • All with an accuracy of 99.7% with an effective shortest turnaround time.

GSeek Breast Cancer Panel

GSeek breast cancer panel simultaneously screens 18 genes that are responsible for inherited predisposition to breast cancer.  The genes covered in the panel include;

BRCA1, BRCA2, TP53, ATM, BARD1, BRIP1, CDH1, CHEK2, MRE11A, MUTYH, NBN, NF1, PAL B2, PTEN, RAD50, RAD51C, RAD51D and STK11.

Breast_cancer_health_photo

Key points

  • Test whether you are genetically predisposed towards breast cancer
  • Credence testing panel covers 18 different genes responsible for breast cancer
  • Comprehensive testing with 99.7% accuracy
  • Best possible action plans if predisposed towards breast cancer
  • Benefit from early diagnosis, reduced medical costs and peace of mind

Did you know?

Outcome of this test provides comprehensive information on an individual’s risk of developing breast cancer during her lifetime.

GSeek ColoRectal

Get in touch

12-3/2 Sunethra Devi Road,
Kohuwala, Sri Lanka.

Phone: 011 2890687 / 011 2818370
Hotline: +94 71 038 0011
Email: info@credencegenomics.com

Search...

Call me back

Please fill out this form if you would want us to call you back.

captcha

Latest News Feed

https://www.credencegenomics.com/news/apollo-india-launches-dna-based-diagnostics-with-sri-lankas-credence-genomics/

Apollo India launches DNA based diagnostics with Sri Lanka’s Credence Genomics

December 3, 2017

Chennai – The Apollo Hospitals Group, India’s largest integrated... Read More

https://www.credencegenomics.com/news/eye-live-interview-dr-vaz-santosh-gnanam-ceo-director-credence-genomics/

EYE LIVE INTERVIEW DR. VAZ SANTOSH GNANAM – CEO / DIRECTOR – CREDENCE GENOMICS

December 2, 2017

Eye Live morning TV show interviewing Dr. Vaz Santosh... Read More

https://www.credencegenomics.com/news/bmc-infectious-diseases-publishes-credence-rid-bactfast-fungifast/

BMC Infectious Diseases publishes Credence RID, Bactfast & Fungifast

December 2, 2017

Credence Genomics Ltd., Sri Lanka’s premier specialised DNA diagnostics... Read More

News Archive

© Credence Genomics 2021. BenWorldwide | Feedback

Thank you

Your inquiry has been received.

Close